Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis

Nature Clinical Practice Rheumatology

Volumn 3, Issue 8, 2007, Pages 434-442

  Lainer Carr, Dahlia ^a   Brahn, Ernest ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; AXITINIB; BEVACIZUMAB; CYCLOSPORIN A; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; HYPOXIA INDUCIBLE FACTOR 1; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PEGAPTANIB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; RANIBIZUMAB; SCATTER FACTOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; VITRONECTIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ARTHRITIS; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HODGKIN DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS; UPREGULATION;

ANGIOPOIETINS; CYCLOHEXANES; EPOXY COMPOUNDS; FATTY ACIDS, UNSATURATED; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INTEGRIN ALPHAVBETA3; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; SESQUITERPENES; SYNOVITIS; TUBULIN MODULATORS; VALINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547555571     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0559     Document Type: Review

References (86)

1. Nagashima M et al. (2000) Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 27: 2339-2342
2. Fox RI and Kang H (1993) Arthritis and Allied Conditions vol. 1, 263-278 (Eds McCarty D and Koopman W) Philadelphia: Lea & Febiger
3. Feldmann et al. (1996) Rheumatoid arthritis. Cell 85: 307-310
4. Fearon U et al. (2003) Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 30: 260-268
5. Peters CL et al. (2004) The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 50: 291-296
6. Walsh DA (1999) Angiogenesis and arthritis. Rheumatology (Oxford) 38: 103-112
7. Middleton J et al. (2004) Endothelial cell phenotypes in the rheumatoid synovium: Activated, angiogenic, apoptotic and leaky. Arthritis Res Ther 6: 60-72
8. Clavel G et al. (2006) Relationship between angiogenesis and inflammation in experimental arthritis. Eur Cytokine Netw 17 202-210
9. Dvorak HF et al. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039
10. Veikkola T and Alitalo K (1999) VEGFs, receptors and angiogenesis. Semin Cancer Biol 9: 211-220
11. Bottomley MJ et al. (1999) Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): Specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol 117: 171-176
12. Ikeda M et al. (2000) Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 191: 426-433
13. Scola MP et al. (2001) Expression of angiogenic factors in juvenile rheumatoid arthritis: Correlation with revascularization of human synovium engrafted into SCID mice. Arthritis Rheum 44: 794-801
14. Berse B et al. (1999) Hypoxia augments cytokine (transforming growth factor-beta [TGF-beta] and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 115: 176-182
15. Cho ML et al. (2006) Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 103: 159-166
16. Ryu S et al. (2006) IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 25: 16-20
17. Levy NS et al. (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273: 6417-6423
18. Paleolog EM et al. (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41: 1258-1265
19. Strunk J et al. (2006) Anti-TNF-alpha antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: A pilot study. Rheumatol Int 26: 252-256
20. Canete JD et al. (2004) Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 50: 1636-1641
21. Grosios K et al. (2004) Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 53: 133-142
22. Holash J et al. (2002) VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398
23. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
24. Suri C et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 1171-1180
25. Davis S et al. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169
26. Maisonpierre PC et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 55-60
27. Debusk LM et al. (2003) Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 48: 2461-2471
28. Gravallese EM et al. (2003) Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 62: 100-107
29. Scott BB et al. (2002) Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 29: 230-239
30. Shahrara S et al. (2002) Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 4: 201-208
31. Scott BB et al. (2005) TNF-alpha modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-kappa B signalling pathway. Biochem Biophys Res Commun 328: 409-414
32. Chen Y et al. (2005) Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 52: 1585-1594
33. Jiang BH et al. (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778
34. Liu LX et al. (2002) Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 291: 908-914
35. Giatromanolaki A et al. (2003) Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 5: R193-R201
36. Hollander AP et al. (2001) Expression of hypoxiainducible factor 1alpha by macrophages in the rheumatoid synovium: Implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 44: 1540-1544
37. Jackson JR et al. (1997) Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol 24: 1253-1259
38. Yeo EJ et al. (2003) YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525
39. Yeo EJ et al. (2004) New anticancer strategies targeting HIF-1. Biochem Pharmacol 68: 1061-1069
40. Mabjeesh NJ et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375
41. Escuin D et al. (2005) Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65: 9021-9028
42. Wilder RL (2002) Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61 (Suppl 2): Ii96-ii99
43. Johnson BA et al. (1993) Adhesion molecule expression in human synovial tissue. Arthritis Rheum 36: 137-146
44. Wu H et al. (1998) Stepwise in vitro affinity maturation of Vitaxin, an αv β3-specific humanized mAb. Proc Natl Acad Sci USA 95: 6037-6042
45. Badger AM et al. (2001) Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum 44: 128-137
46. Storgard CM et al. (1999) Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 103: 47-54
47. Adams JD et al. (1993) Taxol: A history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 15: 141-147
48. Brahn E et al. (1994) Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum 37: 839-845
49. Oliver SJ et al. (1994) Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 157: 291-299
50. Fotsis T et al. (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368: 237-239
51. Josefsson E and Tarkowski A (1997) Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 40: 154-163
52. Brahn E et al. (2006) Angiogenesis inhibition with 2-methoxyestradiol involutes collagen-induced arthritis and suppresses synovial VEGF and FGF-2 gene expression [abstract]. Ann Rheum Dis 65 (Suppl II): 80
53. Ingber D et al. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557
54. de Bandt M et al. (2000) Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 43: 2056-2063
55. Peacock DJ et al. (1992) Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 175: 1135-1138
56. Peacock DJ et al. (1995) A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol 160: 178-184
57. Oliver SJ et al. (1995) Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 166: 196-206
58. Nagashima M et al. (2002) Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab Invest 82: 981-988
59. Hannig G et al. (2007) Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458. Arthritis Rheum 56: 850-860
60. Bernier SG et al. (2004) A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 101: 10768-10773
61. O'Reilly MS et al. (1994) Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328
62. Kim JM et al. (2002) Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 46: 793-801
63. Takahashi H et al. (2005) Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 23: 455-461
64. Kato K et al. (2005) Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. Rheumatol Int 25: 522-529
65. O'Reilly MS et al. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
66. Kurosaka D et al. (2003) Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann Rheum Dis 62: 677-679
67. Matsuno H et al. (2002) Treatment with the angiogenesis inhibitor endostatin: A novel therapy in rheumatoid arthritis. J Rheumatol 29: 890-895
68. Yue L et al. (2004) Anti-adjuvant arthritis of recombinant human endostatin in rats via inhibition of angiogenesis and proinflammatory factors. Acta Pharmacol Sin 25: 1182-1185
69. Gotis-Graham I et al. (1997) Significant correlation between thrombospondin 1 and serine proteinase expression in rheumatoid synovium. Arthritis Rheum 40: 1780-1787
70. Koch AE et al. (1993) Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues. Pathobiology 61: 1-6
71. Koch AE et al. (1998) Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol 86: 199-208
72. Jou IM et al. (2005) Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis Rheum 52: 339-344
73. D'Amato RJ et al. (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085
74. Corral LG et al. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163: 380-386
75. Komorowski J et al. (2006) Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci 78: 2558-2563
76. Oliver SJ et al. (1998) The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol 25: 964-969
77. Hauschild A et al. (1997) Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift. Clin Exp Immunol 108: 428-431
78. Oliver SJ et al. (1999) Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol 118: 315-321
79. Huizinga TW et al. (1996) An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 55: 833-836
80. Kroger H et al. (1996) Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice. Inflammation 20: 203-215
81. Gutierrez-Rodriguez O (1984) Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 27: 1118-1121
82. Gutierrez-Rodriguez O et al. (1989) Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 16: 158-163
83. Huang F et al. (2002) One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 47: 249-254
84. Lehman TJ et al. (2004) Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr 145: 856-857
85. Wei JC et al. (2003) Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial. J Rheumatol 30: 2627-2631
86. Tong Y et al. (2004) Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis. Eur J Pharmacol 494: 101-109